We are pleased to announce the launch of our group company ARCALIS Inc.
https://corp.arcalis.co.jp/

ARCALIS will be a contract development and manufacturing organization (CDMO) focused on mRNA vaccines and therapeutics. ARCALIS is aiming to build its mRNA manufacturing plant in Minamisoma City in Fukushima Prefecture by 2023. Please refer to our press release “Axcelead Decided to Build an mRNA Drug Manufacturing Plant in Minamisoma City, Fukushima Prefecture”